Showing results (171-180 of 189) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|March 20, 2012
Evaluation of treatment options for patients with advanced renal cell carcinoma: assessment of appropriateness, using the validated semi-quantitative RAND corporation/University of California, Los Angeles methodologyM E Gore, J Bellmunt, T Eisen, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 4, 2014
Outcomes from second-line therapy in long-term responders to first-line tyrosine kinase inhibitor in clear-cell metastatic renal cell carcinomaR Elaidi, A Harbaoui, B Beuselinck, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|July 29, 2015
Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysisS Bracarda, R Iacovelli, L Boni, et al.
Nature Biotechnology|March 1, 1997
Plant-derived vaccine protects target animals against a viral diseaseK Dalsgaard, A Uttenthal, T D Jones, et al.
European Journal of Cancer (Oxford, England : 1990)|December 31, 2002
Response to first-line chemotherapy and long-term survival in patients with multiple myeloma: results of the MM87 prospective randomised protocolA Riccardi, O Mora, C Tinelli, et al.
ESMO Open|April 20, 2024
Nivolumab plus cabozantinib versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended follow-up from the phase III randomised CheckMate 9ER trialT Powles, M Burotto, B Escudier, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 13, 2024
Biomarker analyses from the phase III randomized CLEAR trial: lenvatinib plus pembrolizumab versus sunitinib in advanced renal cell carcinomaR J Motzer, C Porta, M Eto, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2025
Final analysis of nivolumab plus cabozantinib for advanced renal cell carcinoma from the randomized phase III CheckMate 9ER trialR J Motzer, B Escudier, M Burotto, et al.
ESMO Open|July 19, 2023
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC studyV Internò, F Massari, R Rudà, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 9, 2012
Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma: a prospective feasibility analysisT Pressiani, C Boni, L Rimassa, et al.
Pageof 19